Universal Vaccines: Shifting to One for Many

Overview

Journal mBio

Publisher American Society for Microbiology

Specialty Microbiology

Date 2010 Aug 7

PMID 20689748

Citations 20

Authors

Antonio Cassone

Rino Rappuoli

Affiliations

Soon will be listed here.

Abstract

Human vaccines, with their exquisite antigenic specificity, have greatly helped to eliminate or dramatically abate the incidence of a number of historical and current plagues, from smallpox to bacterial meningitis. Nonetheless, as new infectious agents emerge and the number of vaccine-preventable diseases increases, the practice and benefits of single-pathogen- or disease-targeted vaccination may be put at risk by constraints of timely production, formulation complexity, and regulatory hurdles. During the last influenza pandemic, extraordinary efforts by vaccine producers and health authorities have had little or no influence on disease prevention or mitigation. Recent research demonstrating the possibility of protecting against all influenza A virus types or even phylogenetically distant pathogens with vaccines based on highly conserved peptide or saccharide sequences is changing our paradigm. "Universal vaccine" strategies could be particularly advantageous to address protection from antibiotic-resistant bacteria and fungi for which no vaccine is currently available.

Citing Articles

Toll-like receptor 4 (TLR4) is the major pattern recognition receptor triggering the protective effect of a extracellular vesicle-based vaccine prototype in murine systemic candidiasis.

Honorato L, Bonilla J, Valdez A, Frases S, Sousa Araujo G, Sabino A mSphere. 2024; 9(8):e0046724.

PMID: 39037263 PMC: 11351041. DOI: 10.1128/msphere.00467-24.

COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control.

Buchy P, Buisson Y, Cintra O, Dwyer D, Nissen M, Ortiz de Lejarazu R Int J Infect Dis. 2021; 112:300-317.

PMID: 34563707 PMC: 8459551. DOI: 10.1016/j.ijid.2021.09.045.

Anti-Infective Antibody-Derived Peptides Active against Endogenous and Exogenous Fungi.

Ciociola T, Giovati L, Conti S, Magliani W Microorganisms. 2021; 9(1).

PMID: 33435157 PMC: 7827253. DOI: 10.3390/microorganisms9010143.

Advances in Fungal Peptide Vaccines.

da Silva L, Taborda C, Nosanchuk J J Fungi (Basel). 2020; 6(3).

PMID: 32722452 PMC: 7558412. DOI: 10.3390/jof6030119.

Protective effect of fungal extracellular vesicles against murine candidiasis.

Vargas G, Honorato L, Guimaraes A, Rodrigues M, Reis F, Vale A Cell Microbiol. 2020; 22(10):e13238.

PMID: 32558196 PMC: 7499402. DOI: 10.1111/cmi.13238.

References

Henderson D, Courtney B, Inglesby T, Toner E, Nuzzo J . Public health and medical responses to the 1957-58 influenza pandemic. Biosecur Bioterror. 2009; 7(3):265-73. DOI: 10.1089/bsp.2009.0729. View

Cassone A, Torosantucci A . Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine. Expert Rev Vaccines. 2006; 5(6):859-67. DOI: 10.1586/14760584.5.6.859. View

Seib K, Dougan G, Rappuoli R . The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLoS Genet. 2009; 5(10):e1000612. PMC: 2752168. DOI: 10.1371/journal.pgen.1000612. View

Lin L, Ibrahim A, Xu X, Farber J, Avanesian V, Baquir B . Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009; 5(12):e1000703. PMC: 2792038. DOI: 10.1371/journal.ppat.1000703. View

Holst J . Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin. 2007; 3(6):290-4. DOI: 10.4161/hv.4513. View

Wu K, Zhang X, Shi J, Li N, Li D, Luo M . Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice. Infect Immun. 2009; 78(3):1276-83. PMC: 2825939. DOI: 10.1128/IAI.00473-09. View

Baquir B, Lin L, Ibrahim A, Fu Y, Avanesian V, Tu A . Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J Infect Dis. 2009; 201(3):473-7. PMC: 2812804. DOI: 10.1086/649901. View

Rachini A, Pietrella D, Lupo P, Torosantucci A, Chiani P, Bromuro C . An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun. 2007; 75(11):5085-94. PMC: 2168274. DOI: 10.1128/IAI.00278-07. View

Huleatt J, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A . Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2007; 26(2):201-14. DOI: 10.1016/j.vaccine.2007.10.062. View

10.

Polonelli L, De Bernardis F, Conti S, Boccanera M, Gerloni M, Morace G . Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol. 1994; 152(6):3175-82. View

11.

Kotturi M, Botten J, Sidney J, Bui H, Giancola L, Maybeno M . A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. PLoS Pathog. 2009; 5(12):e1000695. PMC: 2787016. DOI: 10.1371/journal.ppat.1000695. View

12.

Anderson D, Kaye K . Controlling antimicrobial resistance in the hospital. Infect Dis Clin North Am. 2009; 23(4):847-64, vii-viii. DOI: 10.1016/j.idc.2009.06.005. View

13.

Letourneau S, Im E, Mashishi T, Brereton C, Bridgeman A, Yang H . Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One. 2007; 2(10):e984. PMC: 1991584. DOI: 10.1371/journal.pone.0000984. View

14.

Casadevall A, Pirofski L . Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. Infect Immun. 2007; 75(11):5074-8. PMC: 2168287. DOI: 10.1128/IAI.01001-07. View

15.

Steel J, Lowen A, Wang T, Yondola M, Gao Q, Haye K . Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 2010; 1(1). PMC: 2912658. DOI: 10.1128/mBio.00018-10. View

16.

Polonelli L, Conti S, Gerloni M, Magliani W, Castagnola M, Morace G . 'Antibiobodies': antibiotic-like anti-idiotypic antibodies. J Med Vet Mycol. 1991; 29(4):235-42. DOI: 10.1080/02681219180000351. View

17.

Tan T . Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA. Expert Rev Anti Infect Ther. 2010; 8(2):117-25. DOI: 10.1586/eri.09.132. View

18.

Gening M, Maira-Litran T, Kropec A, Skurnik D, Grout M, Tsvetkov Y . Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens. Infect Immun. 2009; 78(2):764-72. PMC: 2812210. DOI: 10.1128/IAI.01093-09. View

19.

Fiers W, De Filette M, Bakkouri K, Schepens B, Roose K, Schotsaert M . M2e-based universal influenza A vaccine. Vaccine. 2009; 27(45):6280-3. DOI: 10.1016/j.vaccine.2009.07.007. View

20.

Du L, Zhou Y, Jiang S . Research and development of universal influenza vaccines. Microbes Infect. 2010; 12(4):280-6. DOI: 10.1016/j.micinf.2010.01.001. View